Fatostatin, a specific inhibitor binds the SREBP-cleavage activating protein (SCAP) to block cholesterol biosynthesis, is able to inhibit tumor growth in vivo in a mouse prostate cancer experiment (Li et al., 2014). Here, SCAP is linked to prostate carcinoma.